Home › Research › Health systems and care delivery
Role of PCPs in diagnosing dementia in traditional Medicare and Medicare Advantage
Sidra Haye, Mireille Jacobson, Julie Zissimopoulos. Alzheimer s & Dementia, 2025-10-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Among a matched sample of 15,410,030 beneficiaries, accounting for both provider and patient characteristics, the incident dementia diagnosis rate was 0.11 percentage points lower for MA beneficiaries compared to TM beneficiaries attributed to the same PCP. MA patients were less likely to be seen by dementia specialists. Differences in system-level factors such as access to dementia specialists is a contributing factor to differences in diagnosis rates in MA and TM. HIGHLIGHTS: In this study, we quantify how incident dementia diagnosis rates vary for similar beneficiaries in TM and MA seen by the same PCP. To investigate the role of insurance design on dementia diagnosis, we examined differences in diagnosis rates for TM and MA beneficiaries seen by the same PCP. Among a matched sample of TM and MA beneficiaries with assigned PCPs in 2017, incident dementia diagnosis rates were 0.11 percentage points lower for MA beneficiaries compared to TM beneficiaries seen by the same PCP. MA patients were less likely to be seen by dementia specialists compared to TM beneficiaries seen by the same PCP.
What this study adds
Evidence grade: Moderate
This study found that Medicare Advantage beneficiaries were slightly less likely to receive a new dementia diagnosis than similar traditional Medicare beneficiaries seen by the same primary care provider, and were less likely to see dementia specialists. It is about diagnosis patterns, not about treating, curing, or preventing Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Haye, S., Jacobson, M., & Zissimopoulos, J. (2025). Role of PCPs in diagnosing dementia in traditional Medicare and Medicare Advantage. Alzheimer s & Dementia. https://doi.org/10.1002/alz.14559
Vancouver
Haye S, Jacobson M, Zissimopoulos J. Role of PCPs in diagnosing dementia in traditional Medicare and Medicare Advantage. Alzheimer s & Dementia. 2025. doi:10.1002/alz.14559. PMID: 41066196.
BibTeX
@article{haye2025-41066196,
author = {Haye, Sidra and Jacobson, Mireille and Zissimopoulos, Julie},
title = {{Role of PCPs in diagnosing dementia in traditional Medicare and Medicare Advantage}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz.14559},
pmid = {41066196},
url = {https://doi.org/10.1002/alz.14559}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Among a matched sample of 15,410,030 beneficiaries, accounting for both provider and patient characteristics, the incident dementia diagnosis rate was 0.11 percentage points lower for MA beneficiaries compared to TM beneficiaries attributed to the same PCP.
- MA patients were less likely to be seen by dementia specialists.
- Differences in system-level factors such as access to dementia specialists is a contributing factor to differences in diagnosis rates in MA and TM.
- HIGHLIGHTS: In this study, we quantify how incident dementia diagnosis rates vary for similar beneficiaries in TM and MA seen by the same PCP.
- To investigate the role of insurance design on dementia diagnosis, we examined differences in diagnosis rates for TM and MA beneficiaries seen by the same PCP.
Why it matters
This study found that Medicare Advantage beneficiaries were slightly less likely to receive a new dementia diagnosis than similar traditional Medicare beneficiaries seen by the same primary care provider, and were less likely to see dementia specialists. It is about diagnosis patterns, not about treating, curing, or preventing Alzheimer's disease.
Study details
- Evidence strengthModerate
How this study scored 44/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 28 of the 64 points we could judge it on, which is 44 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41066196) |
| Free to read | 2 / 2 | Free to read |
| Points | 28 / 64 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 28 of the 64 points we could judge it on is 44 out of 100. |
| Total | 44 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Health systems and care delivery from nearby years
Also tagged “prevalence”
1,224 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,224 tagged studies.